Cite
HARVARD Citation
Robson, M. et al. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology. pp. 558-566. [Online].